Kaya, One of the Largest Vertical Cannabis Companies in the Caribbean, Introduces Psychedelic Mushroom Chocolate; Updates on Jamaica’s Legal Psilocybin Market
10 mai 2023 08h00 HE
|
NUGL, Inc.
KINGSTON, Jamaica and LOS ANGELES, May 10, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic,...
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
04 mai 2023 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
01 mai 2023 18h52 HE
|
PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
25 avr. 2023 08h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
15 mars 2023 07h30 HE
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
06 mars 2023 07h00 HE
|
Mindset Pharma Inc.
TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized,...
PharmAla Biotech Completes Annual General Meeting
01 mars 2023 08h00 HE
|
PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
01 mars 2023 07h30 HE
|
Optimi Health Corp.
Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
14 févr. 2023 08h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that, in the wake of a landmark decision by the...
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
07 févr. 2023 10h31 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...